OPAL THERAPEUTICS INC

Opal Therapeutics Inc. specializes in advanced therapeutic development and translational research, with a focus on innovative biologics, small-molecule drug candidates, and precision medicine platforms. The company leverages deep expertise in molecular biology, pharmacokinetics, and clinical-stage drug optimization to advance novel therapeutics from preclinical discovery through early-phase human trials. Their technical capabilities include target validation, lead compound screening, formulation development, and regulatory strategy alignment with FDA guidelines. As a woman-owned small business, Opal Therapeutics differentiates itself through agile R&D workflows and a commitment to inclusive innovation in oncology, immunology, and rare disease therapeutics. Award history is not available to determine specific agency engagements or contract patterns, so no direct relationships with federal agencies can be confirmed. However, given the nature of their work, their capabilities align with mission needs of agencies such as NIH, BARDA, and the Department of Defense’s Medical Research and Development Command, which fund early-stage biopharmaceutical innovation. The company operates within the biotechnology and pharmaceutical research sector, with primary focus areas corresponding to NAICS categories related to pharmaceutical and medicine manufacturing and scientific research and development. In practice, this means they develop proprietary therapeutic candidates using GMP-aligned processes and evidence-based preclinical models, positioning themselves as a nimble innovator in the early-stage biotech market. Opal Therapeutics Inc. is structured as a women-owned small business, certified under both the Women-Owned Small Business and Woman-Owned Business programs. Headquartered in San Francisco, California, the company leverages its location in a major biotech innovation hub to access talent, academic partnerships, and venture capital ecosystems. Their certification status enhances their eligibility for set-aside opportunities in federal biomedical research contracting.